Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Role of second bone marrow transplants

M M Shing1, M Vowels

  • 1Department of Haematology and Oncology, Prince of Wales Children's Hospital, Randwick, Australia.

Bone Marrow Transplantation
|July 1, 1993
PubMed
Summary

Second bone marrow transplants (BMT) can achieve long-term remission for patients with relapsed leukaemia or non-malignant diseases. Conditioning regimens like TBI/melphalan show promise for second BMT after initial BU/CY failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment Results in Adolescent and Adult Acute Lymphoblastic Leukaemia Using a Uniform Chemotherapy Protocol.

Leukemia & lymphoma·2016
Same author

Germline TP53 mutations is common in patients with two early-onset primary malignancies.

Clinical genetics·2014
Same author

Ethnicity, equity and public benefit: a critical evaluation of public umbilical cord blood banking in Australia.

Bone marrow transplantation·2007
Same author

Novel cryoprotectant significantly improves the post-thaw recovery and quality of HSC from CB.

Cytotherapy·2006
Same author

TEL/AML1 rearrangement and the prognostic significance in childhood acute lymphoblastic leukemia in Hong Kong.

American journal of hematology·2001
Same author

Rhabdomyolysis following status asthmaticus.

Journal of paediatrics and child health·2001

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Bone marrow transplantation (BMT) is a critical treatment for hematologic malignancies and non-malignant blood disorders.
  • Relapse, graft rejection, and engraftment failure necessitate exploring salvage therapies, including second BMT.
  • Evaluating conditioning regimens is crucial for optimizing outcomes in re-transplantation.

Purpose of the Study:

  • To assess the efficacy and safety of second and third BMT in patients with hematologic malignancies and non-malignant diseases.
  • To compare outcomes based on conditioning regimens used for initial and subsequent BMT.
  • To evaluate the role of autologous rescue in managing engraftment failure.

Main Methods:

  • Retrospective analysis of 15 patients undergoing second or third BMT.
  • Comparison of conditioning regimens: Total Body Irradiation (TBI) with chemotherapy versus Busulphan (BU)/Cyclophosphamide (CY) followed by TBI/Melphalan.
  • Inclusion of patients with relapsed malignancy, graft rejection, and engraftment failure.
  • Assessment of autologous rescue in cases of engraftment failure.

Main Results:

  • Seven patients re-transplanted for relapse: 0/4 conditioned with TBI/Melphalan relapsed, compared to 3/3 conditioned with chemotherapy after initial TBI.
  • Three patients relapsing after first BMT achieved disease-free survival longer than their initial remission.
  • Four patients with non-malignant disease received second allogeneic BMT for engraftment failure; three remain well (24-75 months).
  • Five patients received autologous rescue for engraftment failure; three achieved marrow recovery, with two survivors (41, 77 months).

Conclusions:

  • Second allogeneic BMT can lead to prolonged disease-free survival.
  • TBI/Melphalan appears to be a suitable conditioning therapy for second BMT in patients relapsing after BU/CY.
  • Autologous rescue serves as a valuable safety measure for patients at high risk of engraftment failure.

Related Experiment Videos